Phaseline

Targets › LHCGR

LHCGR (Lutropin-choriogonadotropic hormone receptor): drug programs, companies and trials

5 programs from 5 companies in 5 trials: 2 Phase 2, 2 Phase 3, 1 Phase 4; Genitourinary, Immunology, Metabolic and endocrine; next expected readout Nov 2026.

Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. (UniProt, P22888)

Open in Phaseline: the race on LHCGR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fundacion Clinic per a la Recerca BiomédicaChoriogonadotropin Alfa
Luteinizing hormone/Choriogonadotropin receptor agonist
LHCGRPhase 4InfertilitiesNov 2026
Georgios PapadakisGonadotropin, Chorionic
Luteinizing hormone/Choriogonadotropin receptor agonist
LHCGRPhase 3Klinefelter SyndromeApr 2027
Fundación para la Investigación del Hospital Clínico de ValenciaGonadotropin, Chorionic
Luteinizing hormone/Choriogonadotropin receptor agonist
LHCGRPhase 3Low Ovarian ReserveJul 2027
Clinique OvoHP-hMG (MENOPUR)
Highly purified human menopausal gonadotrophin containing FSH and LH
FSHR, LHCGRPhase 2IVFAug 2027
Hospital Universitario Dr. Jose E. GonzalezGonadotropin, Chorionic
Luteinizing hormone/Choriogonadotropin receptor agonist
LHCGRPhase 2Acute Graft Versus Host Disease–

Conditions

Acute Graft Versus Host Disease (1) Infertilities (1) IVF (1) Low Ovarian Reserve (1) Klinefelter Syndrome (1)

Modalities

small molecule (4), mixed (1)

Companies

Hospital Universitario Dr. Jose E. Gonzalez (1) Fundacion Clinic per a la Recerca Biomédica (1) Clinique Ovo (1) Fundación para la Investigación del Hospital Clínico de Valencia (1) Georgios Papadakis (1)

Related targets

FSHR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.